Neuphoria Therapeutics Inc.
NEUPNASDAQHealthcare● Active
$4.67
+$0.18(+4.01%)
Market Cap$25239253
P/E Ratio—
52W High$21.4
52W Low$3.645
Neuphoria Therapeutics Inc. (NEUP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NEUP · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.09
Est. -$0.56 · +83.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
NEUP reports quarterly as a NASDAQ-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.59B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.59B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2026 | Oct 5, 2026 | -$0.56 | — | — | — | — | — |
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.56 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.56 | -$0.09 | +83.9% | — | — | — |
| ▼ Q1 FY2026 | Feb 17, 2026 | -$0.56 | -$0.77 | -37.5% | — | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.55 | -$4.41 | -701.8% | — | — | — |
| ▼ Q3 FY2025 | Sep 29, 2025 | -$0.56 | -$5.79 | -933.9% | $-0.02B | $0.00B | -6026.1% |
| ▲ Q2 FY2025 | May 20, 2025 | -$0.47 | $6.55 | +1493.6% | $0.01B | $0.00B | +5575.4% |
| ▲ Q1 FY2025 | Mar 17, 2025 | -$2.01 | -$0.01 | +99.6% | $0.00B | $0.00B | +150.7% |
Q4 FY2026
Oct 5, 2026
EPS Actual
—
EPS Est.
-$0.56
EPS Surpr.
—
Revenue
—
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.56
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.09
EPS Est.
-$0.56
EPS Surpr.
+83.9%
Revenue
—
Q1 FY2026
Feb 17, 2026Miss
EPS Actual
-$0.77
EPS Est.
-$0.56
EPS Surpr.
-37.5%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$4.41
EPS Est.
-$0.55
EPS Surpr.
-701.8%
Revenue
—
Q3 FY2025
Sep 29, 2025Miss
EPS Actual
-$5.79
EPS Est.
-$0.56
EPS Surpr.
-933.9%
Revenue
$-0.02B
Q2 FY2025
May 20, 2025Beat
EPS Actual
$6.55
EPS Est.
-$0.47
EPS Surpr.
+1493.6%
Revenue
$0.01B
Q1 FY2025
Mar 17, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$2.01
EPS Surpr.
+99.6%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $-1.18 | $-1.18 | $-1.18 | 1 |
| Q1 FY2027 | $-1.14 | $-1.14 | $-1.14 | 1 |
| Q4 FY2026 | $-1.64 | $-1.64 | $-1.64 | 1 |
| Q3 FY2026 | $-1.58 | $-1.58 | $-1.58 | 1 |
| Q2 FY2026 | $-0.56 | $-0.56 | $-0.56 | 1 |
| Q1 FY2026 | $-0.56 | $-0.56 | $-0.56 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +83.9% | $5.09 | $4.73 | -7.07% |
| ▼ Q1 FY2026 | Feb 17, 2026 | -37.5% | $4.05 | $4.06 | +0.25% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -701.8% | $4.75 | $4.79 | +0.84% |
| ▼ Q3 FY2025 | Sep 29, 2025 | -933.9% | $12.31 | $11.86 | -3.66% |
| ▲ Q2 FY2025 | May 20, 2025 | +1493.6% | $4.92 | $5.40 | +9.76% |
| ▲ Q1 FY2025 | Mar 17, 2025 | +99.6% | $4.72 | $5.00 | +5.93% |
| — Q4 FY2024 | Nov 15, 2024 | — | $3.80 | $3.49 | -8.16% |
| ▼ Q3 FY2024 | Sep 30, 2024 | -156.2% | $7.68 | $5.27 | -31.38% |
Q2 FY2026-7.07%
Report Date
May 15, 2026
EPS Beat/Miss
+83.9%
Price Before
$5.09
Price After
$4.73
Q1 FY2026+0.25%
Report Date
Feb 17, 2026
EPS Beat/Miss
-37.5%
Price Before
$4.05
Price After
$4.06
Q4 FY2025+0.84%
Report Date
Nov 14, 2025
EPS Beat/Miss
-701.8%
Price Before
$4.75
Price After
$4.79
Q3 FY2025-3.66%
Report Date
Sep 29, 2025
EPS Beat/Miss
-933.9%
Price Before
$12.31
Price After
$11.86
Q2 FY2025+9.76%
Report Date
May 20, 2025
EPS Beat/Miss
+1493.6%
Price Before
$4.92
Price After
$5.40
Q1 FY2025+5.93%
Report Date
Mar 17, 2025
EPS Beat/Miss
+99.6%
Price Before
$4.72
Price After
$5.00
Q4 FY2024-8.16%
Report Date
Nov 15, 2024
EPS Beat/Miss
—
Price Before
$3.80
Price After
$3.49
Q3 FY2024-31.38%
Report Date
Sep 30, 2024
EPS Beat/Miss
-156.2%
Price Before
$7.68
Price After
$5.27
Avg Beat Reaction+2.87%
Avg Miss Reaction-8.49%
Beat Rate3 / 8 quarters
Largest Move-31.38% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NEUP ends December
Neuphoria Therapeutics Inc. (NEUP) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.09 — beating the analyst consensus of $-0.56 by +83.9%. The next NEUP earnings date is expected around September 1, 2026.
Each quarter, investors track NEUP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NEUP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NEUP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NEUP earnings · 5 questionsNeuphoria Therapeutics Inc.'s next earnings report is expected around September 1, 2026. NEUP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NEUP historically reports after market close (AMC).
NEUP earnings datewhen is NEUP earningsNEUP next earnings datewhen does NEUP report earningsNEUP earnings calendar
▸ Source: FMP · Neuphoria Therapeutics Inc. SEC filings · US GAAP · Neuphoria Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026